Back to top

gene-therapy: Archive

Zacks Equity Research

CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.

VRTXNegative Net Change CRSPNegative Net Change GMABPositive Net Change IMCRNegative Net Change

Ekta Bagri

3 Genomics Stocks Worth Adding to Your Portfolio in 2025

CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech

ILMNNegative Net Change BEAMNegative Net Change EDITPositive Net Change NTLANegative Net Change PRMENegative Net Change CRSPNegative Net Change